Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 21 years old (the first few patients must be older than 7).
- You must have a brain or spinal cord tumor (like medulloblastoma, high-grade glioma, or ependymoma) that has come back or is growing despite standard treatments.
- You must have already received radiation therapy as part of your initial treatment.
- You must have recovered from side effects of any previous cancer treatments, and at least 2 weeks since your last chemotherapy (or 7 days for biologic agents).
- You must be able to receive more radiation safely, and your doctor thinks it’s a good option.
- You must have a performance score of at least 50 (able to care for yourself or be up in a wheelchair).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
This trial tests if combining focused ultrasound (which opens the blood-brain barrier) with the immunotherapy drug nivolumab can treat relapsed or progressive brainstem gliomas and other high-grade brain tumors in children and young adults.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a short course of radiation (fewer sessions) to help control symptoms from cancer that has spread to the brain or come back in the brain. It is for children and young adults whose cancer cannot be cured, and who are able to do some daily activities.
This trial tests a combination of personalized immune cells, vaccines, stem cells, and an immunotherapy drug (pembrolizumab) for children and young adults whose medulloblastoma has come back or grown. The goal is to help the immune system fight the cancer more effectively.
Hear when a new Medulloblastoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.